CRS: Implementation Of Physical Therapy Protocol In Management Of Chronic Maxillary Sinusitis

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05875298
Collaborator
(none)
66
3
3

Study Details

Study Description

Brief Summary

this study will be conducted to investigate the effect of physical therapy protocol and medication on pain, pressure pain threshold and dysfunction in patients with Chronic Maxillary Sinusitis

Condition or Disease Intervention/Treatment Phase
  • Other: physical therapy protocol
  • Other: physical therapy protocol and medical drugs
  • Other: medical drugs
N/A

Detailed Description

Rhino sinusitis is one of the most common health-care problems worldwide and its prevalence and incidence is increasing. Chronic Sinusitis is a big health problem worldwide that affects almost 15% of humans. The most affected sinus is the maxillary sinus as its drainage orifice through the hiatus semilunaris is badly placed near the roof of the sinus. The first line of treatment for sinusitis is mostly medical drugs including antimicrobial drugs, decongestants, nasal sprays, corticosteroids, and antihistamine drugs which can effectively dry the mucus. Physical therapy also offers a variety of treatment approaches for sinusitis. It includes various electrotherapy modalities, manual drainage techniques, suboccipital release for sinus headaches, needling, and rhino flow therapy. In spite of many studies and treatment approaches done on sinusitis, there are limitations faced in evidence of which approval is most effective, The objective of our study is to investigate the effect of physical therapy protocol in people with chronic maxillary sinusitis.sixty six patients with chronic maxillary sinusitis will be allocated randomly to three groups; one group will receive physical therapy protocol, second one will receive medication only and the third one will receive physical therapy protocol and medication for four weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
physical therapy protocol and medicationphysical therapy protocol and medication
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
opaque sealed envelop
Primary Purpose:
Treatment
Official Title:
Implementation Of Physical Therapy Protocol In Management Of Chronic Maxillary Sinusitis :A Randomized Controlled Trial
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: physical therapy protocol

the patients will receive physical therapy protocol three times a week for four weeks

Other: physical therapy protocol
the patients will receive physical therapy protocol in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus.

Experimental: physical therapy protocol and medical drugs

the patients will receive physical therapy protocol three times a week for four weeks and medication twice daily for four weeks

Other: physical therapy protocol and medical drugs
the patients will receive physical therapy protocol and medical drugs in the form of therapeutic ultrasound (pulsed mode n An intensity of 1.7 W/cm² for maxillary, respectively in A frequency of 1.7 MHz in Duration of treatment of ten minutes for each maxillary sinus and five minutes for each side), Hot pack that will be applied eight minutes at each maxillary area and manual drainage technique for maxillary sinus. The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.

Other: medical drugs
The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.

Active Comparator: medical drugs

the patients will receive medical drugs twice daily for four weeks

Other: medical drugs
The drugs will be concentrated sea water 3% and Local corticosteroids nasal spray.

Outcome Measures

Primary Outcome Measures

  1. pain intensity [up to four weeks]

    by visual analogue scale (VAS) 10 cm line with 2 ends, 0 and 10 ends 0 end means no pain 10 end means the worst pain

  2. pressure pain threshold [up to four weeks]

    pressure algometer will be used to measure pressure pain threshold

  3. functional disability [up to four weeks]

    Rhinosinusitis Disability Index will be used to assess functional disability in patients with chronic maxillary sinusitis.it consists of 30 items divided between three main domains: physical, functional, and emotional. Responses are provided using a 5-point Likert scale, and scores range from 0 to 150, with higher scores indicating that CRS exerts a greater impact on quality of life

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients clinically diagnosed by ENT Physician with chronic maxillary sinusitis With a history of 3 months or longer.

  • Age group from 18 to 50 years

Exclusion Criteria:
  • Local contraindications for face mobilization or massage. (abrasions, skin conditions, broken bones) Medical contraindications. (bacterial infections, conjunctivitis, styes)

  • Duration of onset less than 2 months Headache due to reasons other than chronic sinusitis (TMJD, cervicogenic headache, underlying neurological diseases, anxiety-related, etc)

  • Patients with surgery performed in the past 1 year for maxillary sinusitis Cognition level impairment

  • Metal implants in the face region

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aya Saeed Halmy, principle investigator, Cairo University
ClinicalTrials.gov Identifier:
NCT05875298
Other Study ID Numbers:
  • P.T.REC/012/003842
First Posted:
May 25, 2023
Last Update Posted:
May 25, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Aya Saeed Halmy, principle investigator, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2023